Cellomics, Inc. Names Senior Vice President of Sales & Marketing.

PITTSBURGH--(BW HealthWire)--Dec. 7, 1998--Cellomics, Inc. announced today the appointment of Michael A. Nemzek as Senior Vice President of Sales and Marketing. Mr. Nemzek joins Cellomics after two and a half years with the Perkin-Elmer Corporation where he served as Vice President of Marketing of the Tropix Center of Excellence within the PE Biosystems Division. Mr. Nemzek was previously Vice President of Sales and Marketing of Genosys Biotechnologies, Inc. a leading manufacturer of custom synthetic DNA and peptides. He also has held various management positions with the instruments group of EG&G, Inc.

"Cellomics, Inc. is very pleased to have someone with the experience and track record of Mike join us in this key role as the Company is launching several new products in 1999," stated D. Lansing Taylor, Ph.D., Cellomics' President and CEO. "The addition of Mike as a corporate officer of Cellomics further strengthens our management team to further enable the Company to achieve formidable growth." Mr. Nemzek received his Master of General Administration degree from the University of Maryland, his M.S. in Analytical Chemistry from North Carolina State University and his B.A. in Chemistry from the University of North Carolina at Charlotte.

Cellomics, Inc. is a privately held corporation, founded in October 1996. Cellomics, Inc.'s mission is to improve the efficiency of the drug discovery process by delivering a cell-based screening platform that automates target validation, primary screening and lead optimization using fluorescence-based assays. Today, the Company's integrated platform consists of proprietary fluorescence reagents and assays, a novel, proprietary, cell-based High Content Screening (HCS) system, data management and bioinformatics software. Unlike traditional methods in the drug discovery process, the Company's platform provides deep biological information (time, space, and activity) about a drug candidate's physiological impact on specific cellular targets within living cells. This approach provides significant insight into the potential efficacy and toxicity of a drug candidate on cells before initiating animal testing and human clinical trials, thereby saving substantial time and expense. In addition, the Company co-markets the Carl Zeiss Ultra High Throughput Screening (UHTS) system that can be combined directly with the Cellomics, Inc. HCS system through an exclusive, world-wide alliance with Carl Zeiss Jena, GmbH, the world's leader in optical instrumentation and automation. Cellomics, Inc. will develop new reagents, complete screens, data management tools and bioinformatics as part of the alliance. Combining UHTS with HCS is a new paradigm in drug discovery. The Company is also developing the next generation, cell-based screening platform, the CellChip(TM) System, and the Cellomics(TM) Database to further optimize the drug discovery process.